Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed)

The summary for the Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed): The purpose of this notice of funding opportunity (NOFO) is to support milestone-driven, early-stage translational research focused on drug discovery and development of novel therapeutics against select fungal pathogens including: Candida species, specifically Candida auris; Aspergillus fumigatus; Coccidioides; and Mucorales. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the R33 phase will depend on the successful completion of specific milestones during the R21 phase.
Federal Grant Title: Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-AI-24-065
Type of Funding: Grant
CFDA Numbers: 93.855
CFDA Descriptions: Information not provided
Current Application Deadline: January 28th, 2025
Original Application Deadline: January 28th, 2025
Posted Date: September 23rd, 2024
Creation Date: September 23rd, 2024
Archive Date: March 5th, 2025
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: September 23rd, 2024
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement
https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-065.html
Grant Announcement Contact
NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants
Combating Antibiotic-Resistant Bacteria Interdisciplinary Units (CARBIRUs) (P01 Clinical T...
Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CE...
New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed)
Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Syst...
Strategies for Eliminating HIV Proteins (R21 Clinical Trial Not Allowed)
Center for HIV/AIDS Vaccine Immunology (CHAVI)
Genomics of Transplantation Cooperative Research Program
Asthma and Allergic Diseases Cooperative Research Centers
More Grants from the National Institutes of Health
Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical M...
Combating Antibiotic-Resistant Bacteria Interdisciplinary Units (CARBIRUs) (P01 Clinical T...
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agen...
Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical M...
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optio...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com